Last reviewed · How we verify
Trilafon — Competitive Intelligence Brief
marketed
Phenothiazine [EPC]
D(3) dopamine receptor
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Trilafon (PERPHENAZINE).
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trilafon TARGET | PERPHENAZINE | marketed | Phenothiazine [EPC] | D(3) dopamine receptor | 1957-01-01 | |
| Pramipexole (Mirapex) | Pramipexole (Mirapex) | Massachusetts General Hospital | marketed | Dopamine agonist | D2 dopamine receptor, D3 dopamine receptor | |
| Prolixin Decanoate | FLUPHENAZINE DECANOATE | Bristol-Myers Squibb | marketed | Phenothiazine | D(2) dopamine receptor | 1972-01-01 |
| Thioridazine-2-Sulfoxide | MESORIDAZINE | marketed | Phenothiazine | Histamine H1 receptor | 1970-01-01 | |
| Moditen Enanthate | FLUPHENAZINE ENANTHATE | Bristol-Myers Squibb | marketed | Phenothiazine | D(3) dopamine receptor | 1967-01-01 |
| Prolixin | FLUPHENAZINE | marketed | Phenothiazine | D(3) dopamine receptor | 1959-01-01 | |
| Stelazine | TRIFLUOPERAZINE | marketed | Phenothiazine | D(3) dopamine receptor | 1959-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Phenothiazine [EPC] class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trilafon CI watch — RSS
- Trilafon CI watch — Atom
- Trilafon CI watch — JSON
- Trilafon alone — RSS
- Whole Phenothiazine [EPC] class — RSS
Cite this brief
Drug Landscape (2026). Trilafon — Competitive Intelligence Brief. https://druglandscape.com/ci/perphenazine. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab